Celcuity Inc（CELC）周二盘中股价大涨5.38%，引发投资者广泛关注。这一显著涨幅主要源于该公司在乳腺癌治疗领域取得的重大突破。
根据最新消息，Celcuity公司的先导药物gedatolisib在治疗HR阳性、HER2阴性局部晚期或转移性乳腺癌的三期临床试验（VIKTORIA-1）中取得了积极结果。研究显示，gedatolisib与氟维司群联合使用，无论是否加入CDK4/6抑制剂Ibrance（哌柏西利），都能显著改善患者的无进展生存期（PFS）。
具体来看，三联疗法（gedatolisib、氟维司群和Ibrance）将疾病进展或死亡风险降低了76%，中位PFS从单用氟维司群的2个月延长至9个多月。双联疗法（gedatolisib和氟维司群）的效果也十分显著，降低风险67%，中位PFS为7.4个月。这些数据被专家称为"可能改变临床实践"的结果。
值得注意的是，gedatolisib作为一种静脉注射PI3K/mTOR抑制剂，相比已上市的口服PI3K抑制剂可能具有更广泛的应用前景。Celcuity预计将在年底前向FDA提交申请，如获批准，有望进入一个潜在的50亿美元市场。这一突破性进展大大提升了投资者对Celcuity未来发展的信心，推动了股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.